These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 11237837)

  • 1. Hypertrophy, hyperplasia, and infectious virus in gut-associated lymphoid tissue of mice after oral inoculation with simian-human or bovine-human reassortant rotaviruses.
    Moser CA; Dolfi DV; Di Vietro ML; Heaton PA; Offit PA; Clark HF
    J Infect Dis; 2001 Apr; 183(7):1108-11. PubMed ID: 11237837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rotavirus-specific proteins are detected in murine macrophages in both intestinal and extraintestinal lymphoid tissues.
    Brown KA; Offit PA
    Microb Pathog; 1998 Jun; 24(6):327-31. PubMed ID: 9632536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants.
    Clark HF; Offit PA; Plotkin SA; Heaton PM
    Pediatr Infect Dis J; 2006 Jul; 25(7):577-83. PubMed ID: 16804425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.
    Vesikari T; Clark HF; Offit PA; Dallas MJ; DiStefano DJ; Goveia MG; Ward RL; Schödel F; Karvonen A; Drummond JE; DiNubile MJ; Heaton PM
    Vaccine; 2006 May; 24(22):4821-9. PubMed ID: 16621194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of intestinal rotavirus-specific antibodies in respiratory, but not gut, lymphoid tissues following mucosal immunization of mice with inactivated rotavirus.
    Coffin SE; Clark SL
    Virology; 2001 Dec; 291(2):235-40. PubMed ID: 11878893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of rotavirus immunogenicity by microencapsulation.
    Offit PA; Khoury CA; Moser CA; Clark HF; Kim JE; Speaker TJ
    Virology; 1994 Aug; 203(1):134-43. PubMed ID: 8030269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution and phenotype of rotavirus-specific B cells induced during the antigen-driven primary response to 2/6 virus-like particles administered by the intrarectal and the intranasal routes.
    Di Martino C; Basset C; Ogier A; Charpilienne A; Poncet D; Kohli E
    J Leukoc Biol; 2007 Oct; 82(4):821-8. PubMed ID: 17652448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception.
    Kapikian AZ; Simonsen L; Vesikari T; Hoshino Y; Morens DM; Chanock RM; La Montagne JR; Murphy BR
    J Infect Dis; 2005 Sep; 192 Suppl 1():S22-9. PubMed ID: 16088801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunofluorescence analysis of poliovirus receptor expression in Peyer's patches of humans, primates, and CD155 transgenic mice: implications for poliovirus infection.
    Iwasaki A; Welker R; Mueller S; Linehan M; Nomoto A; Wimmer E
    J Infect Dis; 2002 Sep; 186(5):585-92. PubMed ID: 12195344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine.
    Dennehy PH; Goveia MG; Dallas MJ; Heaton PM
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S36-42. PubMed ID: 18162245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of prion protein in the gut of mice infected orally with the 301V murine strain of the bovine spongiform encephalopathy agent.
    González L; Terry L; Jeffrey M
    J Comp Pathol; 2005 May; 132(4):273-82. PubMed ID: 15893985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine.
    Ciarlet M; Sani-Grosso R; Yuan G; Liu GF; Heaton PM; Gottesdiener KM; Arredondo JL; Schödel F
    Pediatr Infect Dis J; 2008 Oct; 27(10):874-80. PubMed ID: 18756184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea.
    Kim DS; Lee TJ; Kang JH; Kim JH; Lee JH; Ma SH; Kim SY; Kim HM; Shin SM
    Pediatr Infect Dis J; 2008 Feb; 27(2):177-8. PubMed ID: 18174862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of nontypeable rotavirus strains from the United States: identification of a new rotavirus reassortant (P2A[6],G12) and rare P3[9] strains related to bovine rotaviruses.
    Griffin DD; Nakagomi T; Hoshino Y; Nakagomi O; Kirkwood CD; Parashar UD; Glass RI; Gentsch JR;
    Virology; 2002 Mar; 294(2):256-69. PubMed ID: 12009867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children.
    Vesikari T; Karvonen AV; Majuri J; Zeng SQ; Pang XL; Kohberger R; Forrest BD; Hoshino Y; Chanock RM; Kapikian AZ
    J Infect Dis; 2006 Aug; 194(3):370-6. PubMed ID: 16826486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral inoculation of mice with low doses of microencapsulated, noninfectious rotavirus induces virus-specific antibodies in gut-associated lymphoid tissue.
    Khoury CA; Moser CA; Speaker TJ; Offit PA
    J Infect Dis; 1995 Sep; 172(3):870-4. PubMed ID: 7658086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intussusception after administration of the rhesus tetravalent rotavirus vaccine (Rotashield): the search for a pathogenic mechanism.
    Lynch M; Shieh WJ; Bresee JS; Tatti KM; Gentsch JR; Jones T; Jiang B; Hummelman E; Zimmerman CM; Zaki SR; Glass RI
    Pediatrics; 2006 May; 117(5):e827-32. PubMed ID: 16651287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants.
    Clark HF; Bernstein DI; Dennehy PH; Offit P; Pichichero M; Treanor J; Ward RL; Krah DL; Shaw A; Dallas MJ; Laura D; Eiden JJ; Ivanoff N; Kaplan KM; Heaton P
    J Pediatr; 2004 Feb; 144(2):184-90. PubMed ID: 14760258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visualization of peptide presentation following oral application of antigen in normal and Peyer's patches-deficient mice.
    Kunkel D; Kirchhoff D; Nishikawa S; Radbruch A; Scheffold A
    Eur J Immunol; 2003 May; 33(5):1292-301. PubMed ID: 12731054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants.
    Goveia MG; Rodriguez ZM; Dallas MJ; Itzler RF; Boslego JW; Heaton PM; DiNubile MJ;
    Pediatr Infect Dis J; 2007 Dec; 26(12):1099-104. PubMed ID: 18043445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.